GlassScriptPhysician profile
Brittany Buhalog
NPI 1720474513
$6,430.52
in general payments reported to CMS, 2019-2025
24 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2023: $965 · 2024: $2,661 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,822 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,821.57 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $802.77 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $676.19 | 2019-2025 | Tremfya |
| Abbvie INC. | $667.75 | 2019-2025 | Rinvoq |
| Lilly USA, LLC | $535.08 | 2019-2025 | Ebglyss, Taltz, Zepbound |
| Ucb, INC. | $401.03 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $392.69 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $373.25 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $364.23 | 2023-2025 | Absorica Ld, Winlevi |
| Incyte Corporation | $283.90 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $271.71 | 2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $256.78 | 2023-2025 | Zoryve |
| Organogenesis INC. | $214.51 | 2023 | Puraply |
| Amgen INC. | $188.04 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $182.37 | 2025 | Vtama |
| Leo Pharma INC. | $179.05 | 2024-2025 | Adbry, Anzupgo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.34 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $123.13 | 2024-2025 | Aklief |
| Novo Nordisk INC | $110.64 | 2023 | |
| Allergan, INC. | $97.33 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $54.75 | 2024 | Siliq, Duobrii |
| Kerecis Limited | $34.52 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Genentech USA, INC. | $24.99 | 2019 | |
| Dermira, INC. | $23.67 | 2019 | |
| Biofrontera INC. | $8.80 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Buhalog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.